英文_EFPIA_幻灯片_通过信任解锁效率——浏览EMA后授权框架_69页_5mb

EMA Post-Authorization Framework and Reliance Practices

The European Medicines Agency (EMA) webinar on "Unlocking Efficiency through Reliance: Navigating EMA Post-authorization" is scheduled for April 3, 2025, from 13:30 to 15:00 CET. The webinar will cover EMA's post-authorization framework, including variations in drug approvals, transparency, and reliance for different change types.

EMA Post-Authorization Framework:

• Variations Regulation: Last revised in 2012, it now aims for efficiency, future-proofing with scientific/technological progress, and agile review processes.
• Change Types: Variations are categorized (e.g., Type IA, IB, II based on impact), with quality changes downgraded or simplified based on risk/benefit. For biological products, automatic Type II is ending.
• Transparency and Reliance: EMA uses tools like the European Public Assessment Report (EPAR) and reliance documents for different variation types. Efficiencies include in-life updates for annual reports and worksharing procedures.
• Timeframes: Notification pathways typically share work for 20 working days; quality change reviews could shorten timelines, mandating pilot programs for post-approval change management (PACMP).

Egyptian Regulatory Authority Progress:

• The Egyptian Drug Authority (EDA) has achieved World Health Organization transitional listing, joined ICH as an observer, and is working on regulatory maturity.
• EDA is applying a verification route for post-approval changes in Egypt, allowing faster approvals for quality and labeling updates.
• Efficiency gains are shown in PAC submissions; for instance, work output increased 140% after guideline implementation.

Key Changes to Variations Regulation (From Feb 2025 implementation):

• Super-grouping for Type IAs, mandatory annual updates, and market harmonization improvements.
• To support innovation, flexibility is adding regulatory tools like design space inclusion and contact with medical devices, alongside the necessary EMA/CMDh consultations.

5-Year Renewal Process (Post-Approval):

• Legal Basis: MA validity is initially five years; renewal depends on no new public health risks. The assessment re-evaluates benefit/risk balance and updates files.
• Submission: No updates to Module 3 quality data at renewal; instead, MAHs focus on continuous updates. The renewal typically takes 3-5 months.

Overall, reliance strategies and regulatory efficiency aim to streamline processes globally, supported by reforms like EMA's post-regulatory monitoring and Egypt's regulatory goal to adopt international standards.

This summary synthesizes the core elements discussed in the webinar's preview and is based on the unedited content provided.